NCT01588548View on ClinicalTrials.gov

Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Advanced Solid MalignanciesMalignant Lymphoma
Interventions
DRUG

AZD1208

Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose

Trial Locations (3)

Unknown

Research Site, Chūōku

Research Site, Manchester

Research Site, Surrey

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT01588548 - Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma | Biotech Hunter | Biotech Hunter